CAS NO: | 1782070-22-7 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | PAT-505 is a potent, selective, noncompetitive and orally availableautotaxininhibitor, with anIC50of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | PAT-505 is a potent, selective, noncompetitive and orally available autotaxin inhibitor, with an IC50of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma. PAT-505 is selective for ATX versus other ENPP proteins, and shows marginal inhibition of radiolabeled agonist or antagonist binding to the adenosine A3 receptor, MT1 melatonin receptor, prostaglandin E2 EP4 receptor, 5-HT5a serotonin receptor, and GABA-gated Cl-channel with 50%-70% inhibition at 10 μM[1]. | ||||||||||||||||
体内研究 (In Vivo) | PAT-505 suppresses ATX lysoPLD activity with an average IC50value of 62 nM and an average IC90value of 630 nM in mouse plasma, and the IC90in rat plasma is ~770 nM. PAT-505 (30 mg/kg, p.o.) significantly reduces fibrotic score, the percentage of PSR-positive area, and α-SMA immunoreactivity in mouse model of nonalcoholic steatohepatitis (NASH)[1]. | ||||||||||||||||
分子量 | 473.92 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C23H18ClF2N3O2S | ||||||||||||||||
CAS 号 | 1782070-22-7 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 48.33 mg/mL(101.98 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|